Jolanta B. Weglowska

Wroclaw, DS, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.

A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.

Journal: JAAD international

Published: September 13, 2025

Chronic ulceration as a late manifestation of tropical disease.

Chronic ulceration as a late manifestation of tropical disease.

Journal: Postepy dermatologii i alergologii

Published: August 26, 2024

A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.

A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.

Journal: Journal of the American Academy of Dermatology

Published: March 27, 2019

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).

Journal: Journal of the American Academy of Dermatology

Published: December 06, 2017

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.

Journal: The British journal of dermatology

Published: October 25, 2016

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.

Journal: Journal of the American Academy of Dermatology

Published: August 24, 2016

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

Journal: The New England journal of medicine

Published: October 01, 2015

Hypercalciuria in a child with acral peeling skin syndrome: a case report.

Hypercalciuria in a child with acral peeling skin syndrome: a case report.

Journal: Acta dermatovenerologica Croatica : ADC

Published: May 14, 2015

Showing 1-8 of 8

Last Updated: 09/26/2026